Artificial Intelligence In Drug Repurposing Market Is Projected To Grow Robustly By 2033
Artificial intelligence is transforming the pharmaceutical industry by making drug repurposing faster, more accurate, and significantly more cost effective than traditional drug discovery methods. Instead of developing entirely new drugs, researchers are increasingly using AI algorithms to identify new therapeutic uses for existing medicines. This approach shortens development timelines, reduces research costs, and increases the likelihood of successful clinical outcomes.
The growing adoption of machine learning, deep learning, and predictive analytics is helping pharmaceutical companies analyze vast biological datasets, identify hidden drug-disease relationships, and accelerate clinical research. As demand for faster treatment development increases, AI-driven drug repurposing is becoming a strategic priority for both public and private healthcare organizations.
Market Overview
According to Grand View Research, the global artificial intelligence in drug repurposing market was valued at USD 912.4 million in 2025. The market is expected to reach approximately USD 1.05 billion in 2026 and grow to USD 2.89 billion by 2033, registering a CAGR of 15.5% from 2026 to 2033.
North America currently accounts for the largest share of the global market, contributing more than 46% of total revenue, primarily due to its advanced pharmaceutical research ecosystem and early adoption of AI technologies.
Growth Factors
Several factors are accelerating the adoption of artificial intelligence in drug repurposing.
One of the most significant drivers is the rising cost and lengthy development cycle associated with conventional drug discovery. AI allows researchers to evaluate thousands of existing compounds within a much shorter period, significantly reducing both development time and research expenses.
The increasing prevalence of cancer, neurological disorders, infectious diseases, cardiovascular conditions, and rare diseases has created an urgent need for faster therapeutic solutions. AI platforms can rapidly identify promising treatment candidates by analyzing genomic information, clinical trial databases, scientific publications, electronic health records, and molecular interactions.
Growing collaboration between pharmaceutical companies, biotechnology firms, research institutions, and technology providers is also supporting innovation. Increased investments in cloud computing, computational biology, and biomedical data analytics continue strengthening AI-based drug discovery capabilities.
Market Challenges
Despite its rapid expansion, the market faces several important challenges.
- Access to high-quality biomedical datasets remains a major limitation for many research programs. AI models rely heavily on accurate and comprehensive biological information to generate reliable predictions.
- Regulatory approval also presents challenges because AI-generated discoveries still require extensive laboratory validation and clinical testing before commercialization.
- Data privacy regulations, concerns regarding algorithm transparency, integration with existing pharmaceutical workflows, and shortages of skilled AI professionals can further slow adoption.
- Additionally, although AI accelerates candidate identification, successful drug repurposing still depends on extensive scientific validation and regulatory compliance.
Market Segmentation
The artificial intelligence in drug repurposing market is divided into several key segments based on technology, application, deployment model, and end users.
Machine learning currently represents the largest technology segment due to its ability to analyze complex biological relationships and predict drug effectiveness using large datasets. Deep learning, natural language processing, neural networks, and knowledge graph technologies are also becoming increasingly important.
Among therapeutic applications, oncology accounts for the largest market share as pharmaceutical companies increasingly use AI to discover new cancer treatment opportunities from existing medications.
Other important application areas include neurological disorders, infectious diseases, cardiovascular diseases, autoimmune disorders, and rare diseases.
Cloud-based deployment models continue gaining popularity because they provide scalable computing resources, faster data processing, and easier collaboration among research teams located across different regions.
Pharmaceutical and biotechnology companies remain the largest end users, followed by academic research institutions, contract research organizations, and healthcare providers.
Looking for more specific insights? Customize this report to suite your business needs
Regional Analysis
North America continues to lead the global market due to substantial investments in pharmaceutical research, advanced healthcare infrastructure, strong venture capital funding, and the presence of major artificial intelligence companies. The United States remains the largest contributor within the region.
Europe represents another major market, supported by government-funded biomedical research, growing AI adoption, and strong collaboration between universities and pharmaceutical manufacturers. Germany, the United Kingdom, France, Switzerland, and the Netherlands continue driving regional growth.
Asia Pacific is expected to experience the fastest expansion throughout the forecast period. Rapid growth of biotechnology industries, increasing healthcare investments, favorable government initiatives, and expanding pharmaceutical manufacturing are strengthening market demand across China, India, Japan, South Korea, and Singapore.
Latin America is gradually improving its position through increased clinical research activities and expanding digital healthcare infrastructure.
The Middle East and Africa are also witnessing steady growth as governments continue investing in healthcare modernization and biomedical innovation.
Leading Companies
The competitive landscape is characterized by continuous innovation, strategic partnerships, and significant investments in artificial intelligence platforms for pharmaceutical research.
Some of the leading companies operating in the market include:
- BenevolentAI
- Exscientia plc
- Insilico Medicine
- Recursion Pharmaceuticals, Inc.
- Atomwise, Inc.
- Verge Genomics
- Healx Ltd.
- Cyclica Inc.
- BioXcel Therapeutics, Inc.
- Lantern Pharma Inc.
- IBM Corporation
- Microsoft Corporation
- NVIDIA Corporation
- Schrödinger, Inc.
Explore our dedicated business services:
- US Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
- Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
- Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
- Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
- Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
- Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
- Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
Comments
Post a Comment